Overview

• Novartis secured an exclusive worldwide license to Arrowhead’s preclinical ARO-SNCA program with a $200 million upfront payment and the potential for roughly $2 billion in milestones plus royalties.
• Arrowhead will complete preclinical work necessary to enable a clinical trial application, after which Novartis will lead development, manufacturing, medical affairs, and commercialization.
• The agreement allows Novartis to select additional disease targets outside Arrowhead’s current pipeline using Arrowhead’s TRiM RNAi delivery platform.
• The transaction is expected to close in the second half of 2025 subject to the Hart-Scott-Rodino waiting period and other customary conditions.
• Shares of Arrowhead rose more than 9% after the announcement as Novartis turns to novel RNA delivery for Parkinson’s following recent industry trial setbacks.